The latest price target for Viracta Therapeutics (NASDAQ:VIRX) was reported by RBC Capital on November 14, 2024. The analyst firm set a price target for $2.00 expecting VIRX to rise to within 12 months (a possible 1208.04% upside). 8 analyst firms have reported ratings in the last year.

The latest analyst rating for Viracta Therapeutics (NASDAQ:VIRX) was provided by RBC Capital, and Viracta Therapeutics maintained their outperform rating.

There is no last upgrade for Viracta Therapeutics

The last downgrade for Viracta Therapeutics Inc happened on August 16, 2024 when Leerink Partners changed their price target from $5 to $3 for Viracta Therapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Viracta Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Viracta Therapeutics was filed on November 14, 2024 so you should expect the next rating to be made available sometime around November 14, 2025.

While ratings are subjective and will change, the latest Viracta Therapeutics (VIRX) rating was a maintained with a price target of $4.00 to $2.00. The current price Viracta Therapeutics (VIRX) is trading at is $0.15, which is out of the analyst’s predicted range.